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Abstract
Introduction
Aim was to develop a full automatic clustering approach of the time-activity curves (TAC)
from dynamic 18F-FET PET and evaluate its association with IDH1 mutation status and sur-
vival in patients with gliomas.
Methods
Thirty-seven patients (mean age: 45±13 y) with newly diagnosed gliomas and dynamic 18F-
FET PET before any histopathologic investigation or treatment were retrospectively included.
Each dynamic 18F-FET PET was realigned to the first image and spatially normalized in the
Montreal Neurological Institute template. A tumor mask was semi-automatically generated
from Z-score maps. Each brain tumor voxel was clustered in one of the 3 following centroids
using dynamic time warping and k-means clustering (centroid #1: slowly increasing slope;
centroid #2: rapidly increasing followed by slowly decreasing slope; and centroid #3: rapidly
increasing followed by rapidly decreasing slope). The percentage of each dynamic 18F-FET
TAC within tumors and other conventional 18F-FET PET parameters (maximum and mean
tumor-to-brain ratios [TBRmax and TBRmean], time-to-peak [TTP] and slope) was compared
between wild-type and IDH1 mutant tumors. Their prognostic value was assessed in terms of
progression free-survival (PFS) and overall survival (OS) by Kaplan-Meier estimates.
Results
Twenty patients were IDH1 wild-type and 17 IDH1 mutant. Higher percentage of centroid #1
and centroid #3 within tumors were positively (P = 0.016) and negatively (P = 0.01) corre-
lated with IDH1 mutated status. Also, TBRmax, TBRmean, TTP, and slope discriminated
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significantly between tumors with and without IDH1 mutation (P range 0.01 to 0.04). Pro-
gression occurred in 22 patients (59%) at a median of 13.1 months (7.6–37.6 months)
and 13 patients (35%) died from tumor progression. Patients with a percentage of centroid
#1 > 90% had a longer survival compared with those with a percentage of centroid #1 < 90%
(P = 0.003 for PFS and P = 0.028 for OS). This remained significant after stratification on
IDH1 mutation status (P = 0.029 for PFS and P = 0.034 for OS). Compared to other conven-
tional 18F-FET PET parameters, TTP and slope were associated with PFS and OS (P range
0.009 to 0.04).
Conclusions
Based on dynamic 18F-FET PET acquisition, we developed a full automatic clustering
approach of TAC which appears to be a valuable noninvasive diagnostic and prognostic
marker in patients with gliomas.
Introduction
Gliomas constitute the most frequent brain tumors [1] and are heterogeneous in histology,
genetics, and outcome [2]. In particular, the prognostic information of mutations in isocitrate
dehydrogenase (IDH) 1 and 2 has been described by several studies [3]. IDH1 mutation is a
strong and independent predictor of survival [4]. A longer survival is observed in patients with
gliomas harboring the presence of IDH1 or IDH2 mutations [5], whereas the absence of IDH1
appears as a strong predictor for poor prognosis [6]. The World Health Organization has
recently updated Central Nervous System (CNS) classification by integrating these molecular
parameters for diagnostic and prognostic evaluation of gliomas [7].
Compared to 18F-Fluorodeoxyglucose (18F-FDG) which shows high tracer uptake in nor-
mal gray matter, radiolabeled amino acids such as 11C-methionine (11C-MET), 18F-fluoro-L-
dopamine (18F-FDOPA) and 18F-fluoro-ethyl-tyrosine (18F-FET PET) [8,9] exhibit a low
tracer uptake in the normal brain and can depict brain tumors with a high tumor to back-
ground contrast. These tracers are increasingly used in the diagnostic workup of patients with
gliomas, including differential diagnosis, evaluation of tumor extension, treatment planning
and follow-up [10]. They may add some value either for prognostic or classification purposes
[11,12]. The use of amino acid PET was recently recommended by the Response Assessment
in Neuro-Oncology (RANO) working group as an additional tool for evaluating gliomas [13].
As both 18F-FDOPA and 18F-FET are not integrated into any metabolic pathway, FET uptake
signal in tumors is mainly due to perfusion and to the expression of its specialized transporter
namely L-amino acid transporter (LAT) [14]. In particular, the correlation between IDH
mutation status and imaging metabolite remains unclear [15].
Dynamic 18F-FET PET showed some interest for tumor grading [16]. Procedures for imag-
ing with 18F-FET PET usually consist of a dynamic acquisition of 40 to 50 minutes immedi-
ately started after the radiotracer injection. From these acquisitions, time-activity curves
(TAC) can be computed based on regions of interest (ROI) such as 2-dimensional (2D) circu-
lar ROI, 3-dimensional (3D) spherical ROI of 2mL centered by the maximum standardized
uptake value (SUVmax) [17] or fixed threshold which can change but is classically 90% of
SUVmax [18]. From these TAC, some features may be extracted such as time-to-peak (TTP),
maximum activity, area under curve, shape of curve and can be correlated to clinical outcomes
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[19]. IDH1 and 2 mutations were more frequent in tumors with homogeneous increasing
(90%) and focal decreasing (79%) TAC [20]. The pathophysiological mechanisms of these
TAC are not fully known or understood, and may reflect many aspects of tumor microenvi-
ronment such as neoangiogenesis, microvessel density, perfusion and tumor phenotype [21–
23]. Therefore, the main reason for using TAC is a global integration of multiple factors that
could lead to a global tumor phenotype and an individual prognostic based on the shape of the
dominant curve [20]. The shape of curve is classically assessed by a visual analysis [16] and
may be complemented with objective criteria such as TTP or slope [17,20]. To the best of our
knowledge, most of studies have included an analysis of TAC at the tumor level (one TAC for
the whole tumor) but not at the voxel level. Then, aim was to develop a full automatic cluster-
ing approach of TAC from dynamic 18F-FET PET and evaluate its association with IDH1
mutation status and survival in patients with gliomas. Results were secondarily compared to
those of other conventional 18F-FET PET parameters.
Materials and methods
Patients
Between August 2009 and December 2015, a total of 52 patients with suspected primary brain
tumor on conventional magnetic resonance imaging (MRI) were retrospectively enrolled in
this study. Every patient underwent a 18F-FET PET/CT at an initial stage before any planned
subsequent surgical stereotaxic tumor biopsy or any treatment (tumor resection, chemother-
apy, radiotherapy). Patients who required rapid surgery (<2 weeks) due to mass effect or intra-
cerebral hemorrhage, as well as patients with history of brain biopsy, surgery or brain
treatment were excluded. Also, 15 patients with normal and non-segmentable 18F-FET PET
images by our semi-automatic technique were excluded. All patients underwent imaging pro-
cedures as standard care and gave written informed consent before the 18F-FET PET/CT. Col-
lection and analysis of data was retrospective and performed after de-identification. The local
Ethics Research Committee of the State of Vaud took into account the retrospective analysis of
our database, approved the protocol (no. 2017–00758) and waived the requirement for patient
informed consent for the study analysis.
18F-FET PET acquisition
Patients underwent a dynamic 18F-FET PET/CT on Discovery D690 time-of-flight (27
patients) and Discovery LS (10 patients) (GE Healthcare, Waukesha, WI, USA). They were
required to fast for at least 4 hours before undergoing the planned 18F-FET injection as recom-
mended by EANM guidelines [24]. After intravenous injection of 214±25 MBq (range 145–
295 MBq) of 18F-FET, PET images were acquired using a dynamic protocol over 50 minutes
(10 frames of 5 min; 3.3-mm or 4.2-mm section thickness; 24 cm field-of-view, matrix size of
256 × 256). Calibration for the two machines was the same. 18F-FET PET images were recon-
structed by the iterative method ordered-subset expectation maximization (3 iterations and 16
subsets) including a Gaussian post reconstruction filter of 5 mm in full width at half maximum
(FWHM). Raw data were corrected for attenuation by soft-tissue and skull bone using an
unenhanced CT brain (120 kV, 10 mAs), and normalized to the injected dose and body mass
by calculation of the SUV.
Dynamic 18F-FET PET segmentation
All dynamic 18F-FET PET brain image volumes were temporally realigned to the first dynamic
acquisition, coregistered and spatially normalized onto the Montreal Neurological Institute
Voxel-based analysis of 18F-FET PET in gliomas
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template (McGill University, Montreal, Canada). Dimensions of the resulting voxels were
2x2x2 mm3. Images were smoothed using a Gaussian filter (FWHM 8 mm). Preprocessing was
performed using the SPM (SMP12) software implemented in Matlab version R2015a (Math-
works Inc., Sherborn, MA). In order to perform a semi-automatic contouring, a mask for glial
tumor was obtained using Z-score maps (Fig 1A). Z-score maps were obtained from the differ-
ence between each patient static acquisition (which is a summation images from 40 to 50 min-
utes) and an averaged normal 18F-FET PET brain template generated from visually normal
18F-FET PET (absence of abnormal 18F-FET uptake detected by a trained nuclear physician on
static images and t-test parametric image) of 41 patients with untreated gliomas using a Z-
score > 2.5 at the voxel level for tumor delineation and k clusters 250 voxels. Images and
masks were visually controlled by 2 expert brain 18F-FET PET interpreters in consensus, fol-
lowed by a dilatation (3x3x3 structure element with a square connectivity equal to one and 2
iterations) to not miss adjacent pertinent voxels (Fig 1B).
Voxel clustering and extraction of dynamic 18F-FET PET TAC
As we were interested in the shape of the TAC which have shown some interest in differentiat-
ing IDH mutation status [19,20], the tumor proportion of TAC shape was investigated. A non-
supervised approach with k-means clustering to classify each voxel of the tumor mask was
used. As recommended [25], we first normalized from the mean and standard deviation
dynamic 18F-FET PET. Each time series (corresponding to a tumor voxel over the 10-time
frames) was Z-normalized to have a mean set to 0 and a standard deviation to 1 using the fol-
lowing formula T = (T-mean(T)) / std(T) where T is the 10-dimensional vector of tumor voxel
activity over time. Z-normalization is critical to compare time series. Indeed, as empirically
demonstrated by Keogh et al. [26], similarity measure on unnormalized data gives wrong
results.
The number of clusters was fixed a priori and similar time series were clustered together
using dynamic time warping (DTW) Euclidian distance. DTW aims to find the optimal non-
linear alignment between two-time series. More details about DTW are given in S1 Appendix.
K-means algorithm was used for tumor voxel clustering. Therefore, the DTW algorithm with
k-means clustering returns the k centroids that maximize intra-cluster similarity and maxi-
mize inter-cluster dissimilarity. Each voxel was then classified in one of the k centroids based
on the maximization of similarity as measured with Euclidian distance. To find the optimal
number of centroids, in which we wanted that each voxel could be classified, the elbow method
was used (Fig 2A). The elbow method calculates for each value of k (where k is the number of
clusters) the sum of squared errors (SSE) which was obtained by summing the squared error
between each original TAC from tumor voxel and the cluster centroids (produced by the
DTW and k-mean clustering) from which it was the closest. The idea of the elbow method is
to choose the k when the SSE stops decreasing “abruptly”, which produces the so-called "elbow
effect" in the graphics of SSE. Indeed, adding any cluster after this would complicate more the
model without significantly improving performance as measure with SSE. According to the
findings of the elbow method and the well-known different types of tumor TAC which are cur-
rently used to differentiate low-grade gliomas from high-grade [20,27,28] a number of 3 was
set for k, returning 3 centroids and used as main TAC patterns in the current study (Fig 2B).
For convenience reason, we labeled each resultant centroids produced by the DTW algorithm
identically as already mentioned in previous papers [27,28] (Fig 2C): centroid #1: slowly
increasing slope; centroid #2: rapidly increasing followed by slowly decreasing slope; and cen-
troid #3: rapidly increasing followed by rapidly decreasing slope). Each voxel of patients’
tumors ROI was attributed to one of the 3 cluster centroids from which the TAC of that voxel
Voxel-based analysis of 18F-FET PET in gliomas
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was the closest. Then, the number and percentage of each type of centroids for each patient
was computed. To assess the performance of this analysis, results were compared to those of
other conventional 18F-FET PET parameters (maximum and mean tumor-to-brain ratios
[TBRmax and TBRmean], time-to-peak [TTP] and slope) between IDH1 wild-type and IDH1
mutant tumors. As previously described TBR were calculated by dividing the SUVmax and
SUVmean of the tumor by the SUVmean of a larger crescent shape ROI placed in the semioval
centre of the contralateral unaffected hemisphere [29,30]. TTP was the time in minutes from
the beginning of the dynamic acquisition up to the maximum SUV of the lesion. The slope of
Fig 1. Generation of the mask for each tumor. A. Z-score map obtained from SPM12 between each patient and a population-
averaged normal 18F-FET PET brain template. B. The mask obtained from connected regions of previous Z-score map, followed by a
dilatation to not miss adjacent pertinent voxels.
https://doi.org/10.1371/journal.pone.0199379.g001
Fig 2. Voxel clustering and features extraction from dynamic 18F-FET PET. A. The Elbow method, where the abscissa is the time series number and the ordinate
axis the sum of squared errors between each voxel real value and the associated centroid which fitted best the time-activity curve (TAC). Black arrow represents the
break point in the curve, corresponding to 3 clusters centroids. B. The 3 centroids included in the final model; centroid #1: slowly increasing slope; centroid #2:
increasing slope and slowly decreasing slope; centroid #3: rapidly increasing followed by rapidly decreasing curve. C. Centroid #1, centroid #2 and centroid #3 fitted
with 3 TAC (black curves) of voxels.
https://doi.org/10.1371/journal.pone.0199379.g002
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the TAC in the late phase of 18F-FET uptake was quantified by fitting a linear regression line to
the late phase of the curve (20–50 min post-injection) and expressed as SUV/hour [17]. All
these computations were performed using python 2.7 with nilearn- and scikit-learn packages
[31].
Histopathology and determination of IDH1 mutation status
Histopathologic classification and tumor grading were performed according to the World
Health Organization (WHO) guidelines at the respective time point of histopathologic assess-
ment by trained neuropathologists blinded to MRI and 18F-FET PET brain images. All tumors
were classified according to the 2007 WHO classification of tumors of the CNS [32]. IDH1
mutation status was analyzed via immunostaining against the common mutant protein IDH1
variant R132H (anti-IDH1 R132H/DIA-H09, mouse monoclonal anti-brain tumor marker;
Dianova GmbH, Hamburg, Germany).
Statistical analysis
Continuous variables were expressed as median with their 25th-75th interquartile range.
Categorical variables were presented with absolute and relative frequencies. Characteristics
of populations were compared by using Student’s t-test or a bilateral Mann Whitney U test
for quantitative variables and chi-squared for comparison between categorical variables. Prog-
nostic value of dynamic 18F-FET TAC and IDH1 mutation status was assessed in terms of pro-
gression free-survival (PFS) and overall survival (OS). PFS was defined as the time between
initial 18F-FET PET and demonstration of unequivocal tumor progression on follow-up imag-
ing with MRI based on RANO criteria [33] and/or death. OS was defined as time from the
baseline 18F-FET PET until death from any cause. Patients with no known progression or sur-
vival were censored as of their last visit or their last scan date. Survival functions were obtained
from Kaplan-Meier estimates and compared using the log-rank test. Using X-tile software ver-
sion 3.6.1 (Yale University School of Medicine, New Haven, CT) [34], the optimal tumor voxel
percentage of each TAC and the optimal TBRmax, TBRmean, TTP, and slope to predict PFS and
OS served as cutoff to separate high-risk and low-risk patients. All these statistical analyses
were performed using SPSS software (version 23 for Windows 2010, SPSS Inc., Chicago, IL,
USA). A P value < 0.05 was considered statistically significant.
Results
Patient characteristics
Clinical and histopathological data are given in Tables 1 and 2 respectively. Out of the 52
patients included, 37 patients (14 women; mean age: 45±13 y) with positive 18F-FET PET and
histologically proven brain tumor could be segmented and were retained in the final analysis.
Twenty patients were IDH1 wild-type and 17 IDH1 mutant. These subgroups differed in
terms of age (P = 0.04) and number of patients treated with radiochemotherapy (P = 0.003).
Extraction of dynamic 18F-FET PET TAC and association with IDH1
mutation status
For all tumors, the proportion of each centroid is given in Table 2. Example of 2 patients with
anaplastic oligoastrocytoma IDH1 mutant (patient #22) and anaplastic astrocytoma IDH1
wild-type (patient #24) and their spatial repartition of centroid is illustrated in Fig 3. It showed
a higher tumor proportion of centroid #1 (98.6%) in IDH1 mutant tumor and a higher tumor
proportion of centroid #2 and centroid #3 (47.6% and 37.9% respectively) in IDH1 wild-type
Voxel-based analysis of 18F-FET PET in gliomas
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tumor. As shown in Fig 4 using boxplots, the automatic voxel clustering based on the 3 fixed
centroids confirmed that a higher percentage of tumor voxel with centroid #1 and centroid #3
was positively (P = 0.016) and negatively (P = 0.01) correlated with the IDH1 mutant status
respectively. No difference was found with centroid #2 (P = 0.13). As shown in Table 3,
TBRmax, TBRmean, TTP, and slope discriminated significantly between IDH1 wild-type and
IDH1 mutant tumors (P range 0.01 to 0.04).
Association with survival
The median (25th-75th interquartile range) duration of follow-up was 22.5 months (11.8–38.4
months). Relapse/progression occurred in 22 patients (59%) at a median of 13.1 months (7.6–
37.6 months) and 13 patients (35%) died from tumor progression. As shown in Fig 5, Kaplan-
Meier estimates revealed that patients with IDH1 mutant tumors had a significant longer PFS
(P = 0.001) and OS (P = 0.004) than IDH1 wild-type. Also, using X-tile software, a single opti-
mal threshold was defined and showed that patients with a higher percentage of tumor voxel
with centroid #1> 90% had a longer PFS (P = 0.003) and OS (P = 0.028) due to the higher
number of IDH1 mutant tumors (77% vs. 29% in patients with tumor voxel percentage of cen-
troid #1 < 90%, P = 0.005). This remained significant after stratification on IDH1 mutation
status (P = 0.029 for PFS and P = 0.034 for OS). Compared to other conventional 18F-FET PET
parameters, only TTP and slope were associated with PFS and OS (P range 0.009 to 0.04, Fig
6).
Discussion
Using an automatic clustering of TAC, we aimed at investigating the association between
dynamic 18F-FET PET findings of whole-tumor voxels, IDH1 mutation status and survival in
patients with gliomas. This kind of approach already has been proposed for MRI or 18F-FDG
PET [35], however to the best of our knowledge, this is the first time it has been used for
18F-FET PET. This method can be easily applied for clinical routine. A trained physician can
perform all the necessary steps from spatial normalization to segmentation in less than 5 min-
utes. The automatic TAC clustering, once it is firstly trained (to get the main centroids), is a
matter of seconds. This method, as doesn’t involve physicians, is less subjective to bias com-
pared to visual analysis, appears more reproducible and becomes integrated perfectly into the
Table 1. Population characteristics.
Characteristics All patients
(n = 37)
IDH1 wild-type tumors
(n = 20)
IDH1 mutant tumors
(n = 17)
P value
Age 44.7 (36;53) 49.1 (40–59) 42.6 (36–45) 0.04
Female gender 14 (37.8) 8 (40) 6 (35.3) 0.77
Delay between 18F-FET PET and histopathological diagnosis 1.1 (0.5;1.7) 0.8 (0.2–1.3) 1.4 (1.0–2.1) 0.49
Treatments
Surgery 6 (16.2) 1 (5) 5 (29.4) 0.05
Radiochemotherapy 11 (29.7) 10 (50) 1 (5.9) 0.003
Chemotherapy 9 (24.3) 4 (20) 5 (29.4) 0.51
Surgery + radiochemotherapy 8 (21.6) 3 (15) 5 (29.4) 0.65
None 3 (8.1) 2 (10) 1 (5.9) 0.29
Values are median (25th-75th interquartile range) or n (%).
expressed as months
IDH, isocitrate dehydrogenase
https://doi.org/10.1371/journal.pone.0199379.t001
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Table 2. Histopathological and 18F-FET PET data.
Histopathological data 18F-FET PET data
# Type MIB-1 IDH1
mutation
WHO
grade
Centroid
#1 (%)
Centroid
#2 (%)
Centroid
#3 (%)
SUVmax
(g/ml)
SUVmean
(g/ml)
TBRmax TBRmean TTP
(min)
Slope
(SUV/
h)
1 Oligodendroglioma 5 + II 98.2 0.1 1.7 3.6 2.1 4.1 2.4 45 1.23
2 Anaplastic
astrocytoma
20 - III 5.2 54.6 40.2 2.4 1.5 4.0 2.5 15 -0.72
3 Anaplastic
astrocytoma
5 - III 27.3 70.8 1.9 2.2 1.8 2.4 2.0 25 -0.43
4 Oligodendroglioma 15 + II 7.5 57.4 35.1 3.4 2.1 3.8 2.3 15 -0.28
5 Low-grade glioma 0 + I 97.2 0 2.8 1.4 1.1 1.6 1.2 30 0.14
6 Anaplastic
oligoastrocytoma
Unknown + III 95.3 4.7 0 4.0 2.2 3.1 1.7 45 0.05
7 Secondary
glioblastoma
15 + IV 100 0 0 1.1 1.0 1.2 1.1 45 0.35
8 Anaplastic
oligoastrocytoma
10 + III 5.2 33.9 60.9 1.7 1.2 2.4 1.7 10 -0.32
9 Primary glioblastoma 30 - IV 99.9 0 0.1 3.7 2.1 4.4 2.6 45 0.79
10 Anaplastic
oligodendroglioma
60 - III 54.3 45.7 0 2.3 1.6 3.3 2.3 35 -0.26
11 Oligoastrocytoma 15 + II 71.7 28.3 0 2.2 1.7 2.8 2.1 40 0.11
12 Oligoastrocytoma 15 - II 10.9 24.8 64.3 2.9 2.1 3.3 2.5 10 -0.83
13 Primary glioblastoma 40 - IV 27.6 31.3 41.1 2.4 1.6 3.0 2.0 10 -0.61
14 Anaplastic
oligoastrocytoma
30 - III 89.9 9.7 0.4 2.4 1.9 2.0 1.6 45 -0.07
15 Anaplastic
oligodendroglioma
60 - III 15.5 33.5 51 2.5 1.8 3.2 2.1 10 -0.65
16 Oligoastrocytoma 10 - II 11.8 28.8 59.4 3.3 2.0 4.1 2.5 10 -0.96
17 Oligodendroglioma 10 + II 14.6 83 2.4 2.6 1.4 2.9 1.6 15 -1.01
18 Anaplastic
astrocytoma
10 + III 12.6 85.7 1.7 2.2 1.7 1.8 1.4 20 0.06
19 Anaplastic
astrocytoma
40 - III 81.9 10.2 7.9 4.0 2.3 6.7 3.8 40 0.55
20 Diffuse astrocytoma 5 - II 21.1 66.4 12.5 3.3 2.4 3.7 2.6 20 -1.16
21 Ganglioglioma 2 - II 1.8 28.9 69.3 2.6 1.5 4.3 2.5 10 -0.70
22 Anaplastic
oligoastrocytoma
2 + III 98.6 0.1 1.3 2.2 1.7 2.4 1.9 45 1.11
23 Low-grade glioma 3 - I 6.5 76.7 16.8 2.6 1.9 2.9 2.1 15 -0.50
24 Anaplastic
astrocytoma
10 - III 14.5 47.6 37.9 2.4 1.6 3.4 2.3 15 -0.68
25 Anaplastic
oligodendroglioma
20 + III 42.2 28.8 29 3.5 2.3 3.9 2.5 20 -0.91
26 Oligodendroglioma 3 + II 98.8 1.1 0.1 2.7 2.0 3.4 2.5 45 0.34
27 Gemistocytic
astrocytoma
0 + II 93.5 6.5 0 2.2 1.7 2.9 2.2 35 0.32
28 Oligoastrocytoma 1 + II 100 0 0 1.6 1.4 2.3 2.0 45 0.56
29 Oligoastrocytoma 10 + II 97.2 2.7 0.1 3.3 2.2 3.4 2.1 45 0.34
30 Primary glioblastoma 30 - IV 9.3 50.3 40.4 5.4 2.9 5.3 2.8 10 -0.94
31 Oligoastrocytoma 10 - II 93.5 3.3 3.2 4.5 3.3 4.9 3.8 40 0.43
32 Diffuse astrocytoma 3 - II 0 0.1 99.9 1.4 1.2 1.9 1.4 5 -0.66
33 SEGA 1 - I 100 0 0 2.9 1.8 4.1 2.6 45 0.54
34 Oligodendroglioma 5 + II 92.5 7.5 0 2.2 1.8 2.8 2.3 45 0.13
(Continued)
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new area of large database. Also, as data were normalized, this kind of approach is more homo-
geneous between different centers and allows more feasible multicenter clinical trials.
Advantages of voxel-wise analysis of TAC include more precise characterization of tumor
phenotypes and more precise assessment of survival. Indeed, when considering the whole
tumor ROI for extracting the TAC, in 34 patients out of 37, the TAC’s shape of the whole
tumor was in accordance with the predominant TAC (the one with the highest proportion).
The whole tumor TAC shape didn’t reflect the majority of the voxels shape TAC in 3 patients.
For example, in one patient with anaplastic astrocytoma IDH1 wild-type (patient #37), the
extracted TAC was centroid #2 when considering a ROI on the whole tumor. When consider-
ing the proportion of each centroid, his prognosis was more defined. With a predominant cen-
troid # 1 of 50.6%, the patient was classified as high-risk (as it was less than the threshold of
90%). Follow-up confirmed his worse survival with a low PFS and OS (3.4 and 13.8 months
respectively). This discrepancy between both analyses may be explained by the fact that when a
Table 2. (Continued)
Histopathological data 18F-FET PET data
# Type MIB-1 IDH1
mutation
WHO
grade
Centroid
#1 (%)
Centroid
#2 (%)
Centroid
#3 (%)
SUVmax
(g/ml)
SUVmean
(g/ml)
TBRmax TBRmean TTP
(min)
Slope
(SUV/
h)
35 Anaplastic
oligoastrocytoma
8 + III 30.8 57.1 12.1 1.8 1.4 2.6 2.0 25 -0.08
36 Primary glioblastoma 80 - IV 73.5 26.5 0 1.9 1.4 2.7 2.0 45 -0.31
37 Anaplastic
astrocytoma
40 - III 50.6 22.5 26.9 2.1 1.8 2.2 1.9 20 0.04
IDH, isocitrate dehydrogenase; WHO, World Health Organization; SEGA, subependymal giant cell astrocytoma; SUV, standardized uptake value; TBR, tumor-to-brain
ratio; TTP, time-to-peak;
malignant transformation from oligodendroglioma;
 tumor proportion of each centroid
https://doi.org/10.1371/journal.pone.0199379.t002
Fig 3. Example of 2 patients with anaplastic oligoastrocytoma IDH1 mutant (patient #22) and anaplastic
astrocytoma IDH1 wild-type (patient #24) and their spatial repartition of centroid (blue: Tumor repartition of
centroid #1, green: Tumor repartition of centroid #2, grey: Tumor repartition of centroid #3).
https://doi.org/10.1371/journal.pone.0199379.g003
Voxel-based analysis of 18F-FET PET in gliomas
PLOS ONE | https://doi.org/10.1371/journal.pone.0199379 June 28, 2018 9 / 16
full ROI is taken, data are summed and some local variations of voxel of lower intensity may
be lost. Then, retained information are the ones of the most actives voxels.
Shapes of TAC are not yet fully understood and are hypothesized to reflect many aspects of
tumor microenvironment and tumor phenotype. Using PET MRI scan, Zhang et al. [23]
reported that a positive correlation (r = 0.53; P = 0.002) was found on 2D ROI between
18F-FET PET tumor-to-brain ratio and regional cerebral blood flow as measured using arterial
spin labeling. Nevertheless, as shown with the Pearson product moment “r”, even if there
might be a positive correlation, it remained weak and didn’t fully reflect the pathophysiological
complexity of gliomas. Xiong et al. found that IDH mutant tumors had also a lower microvas-
cular density [36]. These findings are in accordance with our study as a lower microvascular
density could lead, all other things equal otherwise, to a lower perfusion and therefore to a
lower uptake and slope of shape. Our IDH1 mutant tumors had a lower 18F-FET uptake and as
they were composed of majority of centroid #1 (with the lowest initial slope) and less centroid
#3 (high initial slope). The centroid #3 is classically described as a high wash-out curve which
may reflect local tumor aggressiveness due to a higher perfusion and an increased metabolic
turnover in tumor cells. Also, our results are in line with those observed by Thon et al. [20], as
the ascending curves would correspond to our centroid #1 and had a better prognosis in term
of PFS (85% 2-year survival for homogeneous increasing TAC against 51% for focal decreasing
TAC and 28% for homogeneous decreasing TAC).
IDH1 mutant tumors had a lower 18F-FET uptake in our cohort (Table 3). IDH1 and IDH2
belong to the NADP+- dependent IDH isoforms which are found in the cytosol for IDH1 and
mitochondria for IDH2. IDH1 and IDH2 produce NADPH by catalyzing the oxidative decar-
boxylation of isocitrate to α-oxoglutarate (OG) outside of the Krebs cycle. NADPH plays a
substantial role in cellular control of oxidative damage. Loss of enzyme activity due to the
dominant negative effect of IDH mutants leads to a new enzymatic activity transforming α-
cetoglutarate into 2-hydroxyglutarate (2-HG). This leads to an inhibition of the 2-OG
Fig 4. Association with IDH1 mutation status. Boxplots with percentage of tumor voxels with centroids #1, #2 and #3 (from left to right) according to the IDH1
mutation status.
https://doi.org/10.1371/journal.pone.0199379.g004
Table 3. Association with IDH1 mutation status.
All patients IDH1 wild-type tumors IDH1 mutant tumors P value
TBRmax 2.9 (2.4;3.6) 3.3 (2.7;4.1) 2.6 (2.2;3.3) 0.02
TBRmean 2.1 (1.7;2.3) 2.2 (2;2.5) 1.9 (1.7;2.2) 0.02
TTP (min) 25 (15;45) 17.5 (10;40) 40 (20;45) 0.04
Slope (SUV/h) -0.08 (-0.66;0.34) -0.56 (-0.7;-0.05) 0.13 (-0.08;0.35) 0.01
Values are median (25th;75th interquartile range)
SUV, standard uptake value; TBR, tumor-to-brain ratio; TTP, time-to-peak
https://doi.org/10.1371/journal.pone.0199379.t003
Voxel-based analysis of 18F-FET PET in gliomas
PLOS ONE | https://doi.org/10.1371/journal.pone.0199379 June 28, 2018 10 / 16
Fig 5. Kaplan-Meier estimates of progression-free survival (PFS) and overall survival (OS) according to IDH1 mutation (upper panel) status and
tumor percentage of centroid #1 (lower panel).  NR = Not reached due to the lack of event.
https://doi.org/10.1371/journal.pone.0199379.g005
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Fig 6. Kaplan-Meier estimates of progression-free survival (PFS) and overall survival (OS) according to other
conventional 18F-FET PET parameters (TBRmax, TBRmean, TTP, and slope).
 NR = Not reached due to the lack of
event.
https://doi.org/10.1371/journal.pone.0199379.g006
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dependent enzymes and may act as an oncometabolite with alternative molecular pathways
[37] that may influence amino acid tracer uptake in the tumor [15]. Controversial results have
been described for the effect of IDH mutant on the hypoxia-inducible factor (HIF) pathway
which is known to stimulate the expression of glucose transporter (GLUT) and LAT. Indeed,
as 18F-FET is not metabolized nor stocked, its signal only depends on the expression of the
LAT and the intra/extracellular concentration of 18F-FET. IDH1 appears to function as a
tumor suppressor that, when mutationally inactivated, contributes to tumorigenesis in part
through the induction of the HIF-1 pathway. Zhao et al. reported that overexpression of IDH
mutant in U87M glioma cells increased HIF-1α target expression proteins [38]. Nevertheless,
another study showed that R-2HG that would promote the activation of EGLN1-2 or 3, which
would result in the degradation of HIF-1α. Analysis of the gene expression from the TCGA
data archives revealed that tumors expressing the IDH mutant had a reduced expression of
HIF target genes compared to tumors containing IDH wild-type [39]. HIF is known to be
related to the metabolism enzyme, particularly GLUT, but also LAT and even if its role remain
unclear, it have been described in other cancers such as mesotheliomas or lung cancer [40].
Other amino acid tracers have been investigated. Recently, in 109 patients with gliomas, Lopci
et al. showed that 11C-MET PET parameters were significantly correlated with histological
grade and IDH1 mutation status. In this cohort, even if it didn’t reach the significance level
(P = 0.05), SUVmax seemed to be inversely correlated with the presence of IDH1 mutation in
this cohort [41]. Also, Verger et al. [42] found that IDH mutations were paradoxically corre-
lated with a higher 18F-FDOPA uptake in diffuse gliomas. The apparent discrepancy between
the uptake pattern of 18F-FET, 11C-MET and 18F-FDOPA may be linked to the metabolomic
profile of IDH mutant tumors [15].
The current study had several limitations. The main limitation was the retrospective nature
of the data collection that may have introduced a selection bias. Secondly, as some 18F-FET
PET were visually normal and confirmed with normal Z-score maps, it was impossible to
delineate 15 patients out of the 52 patients initially included. This may also have included a
selection bias. Thirdly, we may criticize the generation of the “normal FET population” using
41 patients with visually normal 18F-FET PET and untreated gliomas. Indeed, those patients
had abnormal MRI but which didn’t show any metabolic rendering. Nevertheless, using SPM,
it was checked that each patient didn’t statistically differ from the 40 other patients and we do
not think that it shall impact greatly on the final ROI because of the voxel that may be missed
would be the ones with the smallest intensity value. Fourthly, glioblastomas (5 patients) which
are classically IDH wild-type (90% of glioblastomas) for primary subtype, are highly metabolic
tumors with a high amino acid metabolism and are associated with a poorer prognosis. Never-
theless, removing them didn’t change the significance level of our findings in an additional
analysis. Two different PET/CT scanners were used in this study. It has been verified that the
mean activity was not statistically different between both machines. After preprocessing, the
resulting voxel were downsampled to the same size. All data were normalized from mean
which shouldn’t impact the shape and tumor proportion of TAC. As no normalization was
performed on the unnormalized data to compare the mean tumor activity between IDH1
wild-type and IDH1 mutant, it has been checked (data not shown) that activity was not statisti-
cally different between both PET/CT scanners. Also, the proportion of IDH1 mutant tumors
was split equally between both PET/CT machines.
Conclusion
In conclusion, based on dynamic 18F-FET PET acquisition, we developed a full automatic clus-
tering approach of TAC which appears to be a valuable noninvasive diagnostic (for IDH1
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mutant status) and prognostic marker in patients with gliomas. Further larger prospective
studies are warranted to validate these findings.
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S1 Appendix. Dynamic time warping (DTW). DTW aims to find a non-linear agreement
between two-time series. Let’s consider two time series Q and C with the same number of time
points n where Q = q1, q2. . ., qn and C = c1, c2 . . ., cn, it can build the M matrix of dimension
n×n matrix whose i, jth element is the Euclidean distance between qi and cj. Therefore, objec-
tive of DTW aims to find the path through M that minimizes the cumulative distance. The
optimal path is found following recursive function: γ(i,j) = d(qi,cj) + min(γ(i−1,j−1), γ(i−1,j), γ
(i,j−1)).
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